Regeneron Pharmaceuticals' Non Operating Income rose 130.92% to $755.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 43.73%. This contributed to the annual value of $844.4 million for FY2024, which is 274.96% up from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Non Operating Income is $755.8 million, which was up 70.69% from $442.8 million recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Non Operating Income ranged from a high of $755.8 million in Q3 2025 and a low of -$197.4 million during Q1 2022.
For the 3-year period, Regeneron Pharmaceuticals' Non Operating Income averaged around $232.4 million, with its median value being $193.0 million (2023).
Its Non Operating Income has fluctuated over the past 5 years, first crashed by 268.78% in 2021, then soared by 1,759.66% in 2024.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Non Operating Income stood at -$122.2 million in 2021, then skyrocketed by 294.19% to $237.3 million in 2022, then decreased by 18.67% to $193.0 million in 2023, then tumbled by 111.19% to -$21.6 million in 2024, then surged by 130.92% to $755.8 million in 2025.
Its Non Operating Income was $755.8 million in Q3 2025, compared to $442.8 million in Q2 2025 and $322.0 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value